Skip to search formSkip to main contentSkip to account menu

JM 216

Known as: JM-126, JM-216, JM216 
National Institutes of Health

Related topics

Related topics

2 relations
BMS-182751

Broader (1)

satraplatin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
From selection of patients with non-small-cell lung cancer to the cost of treatment in Portugal: evaluation of second and third lines treatment.
Lung cancer is the most common form of cancer death in the world. Five-year survival is about 15%, without any change to this… 
2000
2000
Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy
Purpose: We evaluated the orally administered platinum agent, JM216, in combination with ionizing radiation both in vivo and in… 
2000
2000
Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients
Purpose: The purpose of this study was to assess renal function in patients treated with the oral platinum drug JM216 [bisacetato… 
2000
2000
Inhibitory effect of JM216 on human ovarian tumor HO-8910
Objective:To investigate the cytotoxicity of bis acetato ammine dichloro cyclohexylamine platinum Ⅳ(JM216) on human ovarian… 
1996
1996
Interfacing high performance liquid chromatography with inductively coupled plasma mass spectrometry for speciation studies
Fisons Instruments Elemental, Ion Path Road 3, Winsford, Cheshire, CW7 3BX and Johnson Matthey Technology Centre, Blounts… 
1995
1995
Pharmacokinetic Study of Orally Administered Ammine Diacetatodichloro(cyclo-hexylamine)platinum IV (JM216) in a 5-Day Dose Schedule Phase I Clinical Trial
1995
1995
Synthesis of Pt-191 labelled JM216, an orally active anti-tumour Compound
1995
1995
The tissue distribution in mice of C-14 labelled JM216 an orally active anti-tumour compound